Literature DB >> 18552465

Insulin resistance is the major determinant for microalbuminuria in severe hypertriglyceridemia: implication for high-risk stratification.

Chien-Yu Lin1, Ming-Fong Chen, Lian-Yu Lin, Chiau-Suong Liau, Yuan-Teh Lee, Ta-Chen Su.   

Abstract

OBJECTIVE: The significance of high triglyceride levels as a risk factor for coronary heart disease is uncertain. We hypothesized that oral glucose tolerance test (OGTT) and certain novel markers may help to identify high-risk patients. PATIENTS AND METHODS: We recruited 80 subjects with severe hypertriglyceridemia (age 27-73 years) without clinical proteinuria and diabetes mellitus (DM) which were diagnosed by fasting glucose <126 mg/dL from Hyperlipidemia Clinic of National Taiwan University Hospital for this study. We applied OGTT to evaluate occult DM and homeostasis model assessment (HOMA)-insulin resistance (IR) score to evaluate insulin resistance, and the measurements of microalbuminuria as a marker of vascular damage. In addition, serum or plasma markers of inflammation and fibrinolysis, fasting glucose and insulin as well as traditional cardiovascular risk factors were also evaluated.
RESULTS: The serum level of triglyceride was higher in patients with microalbuminuria than in those without (14.1+/-5.7 vs. 9.6+/-3.9 mmol/L, p=0.025). Patients with microalbuminuria had higher fasting blood glucose and insulin, higher post-OGTT glucose and insulin, higher prevalence of newly developed diabetes mellitus (DM) (39% vs. 11%, p=0.007) and higher HOMA-IR (6.2+/-4.4 vs. 3.3+/-2.0, p<0.001). Among all the inflammatory and fibrinolytic markers, only soluble intercellular adhesion molecule showed significant different between these two groups. Multiple logistic regression analysis showed that among the serum markers, only HOMA-IR level was significantly related to microalbuminuria.
CONCLUSIONS: HOMA-IR is the major determinant for microalbuminuria in patients with severe hypertriglyceridemia. Impaired glucose metabolism is evident in patients with both severe hypertriglyceridemia and microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552465     DOI: 10.2169/internalmedicine.47.0696

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Insulin resistance is associated with the development of albuminuria in Korean subjects without diabetes.

Authors:  Cheol Min Jang; Young Youl Hyun; Kyu Beck Lee; Hyang Kim
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

2.  Effect of diacylglycerol supplementation on fasting serum triacylglycerol concentration: a meta-analysis.

Authors:  Wenliang Wang; Tongcheng Xu; Xia Li; Qingjun Zhu; Anwei Cheng; Fangling Du; Duo Li
Journal:  Lipids       Date:  2010-11-13       Impact factor: 1.880

3.  Elevated brachial-ankle pulse wave velocity is independently associated with microalbuminuria in a rural population.

Authors:  Joo Youn Seo; Mi Kyung Kim; Bo Youl Choi; Yu-Mi Kim; Sung-Il Cho; Jinho Shin
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

4.  Maternal inheritance of severe hypertriglyceridemia impairs glucose metabolism in offspring.

Authors:  Ya-Hong Ma; Caiguo Yu; Abudurexiti Kayoumu; Xin Guo; Zhili Ji; George Liu
Journal:  J Biomed Res       Date:  2015-03-13

5.  A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.

Authors:  Ta-Chen Su; Juey-Jen Hwang; Kuo-Chin Huang; Fu-Tien Chiang; Kuo-Liong Chien; Kuo-Yang Wang; Min-Ji Charng; Wei-Chuan Tsai; Lian-Yu Lin; Runar Vige; José Emilio Ruiz Olivar; Chuen-Den Tseng
Journal:  J Atheroscler Thromb       Date:  2016-09-06       Impact factor: 4.928

6.  Association between Brachial-Ankle Pulse Wave Velocity and Microalbuminuria and to Predict the Risk for the Development of Microalbuminuria Using Brachial-Ankle Pulse Wave Velocity Measurement in Type 2 Diabetes Mellitus Patients.

Authors:  Byong-Kyu Kim; Dilaram Acharya; Deuk-Young Nah; Moo-Yong Rhee; Seok-Ju Yoo; Kwan Lee
Journal:  Healthcare (Basel)       Date:  2019-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.